Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

CRSP CRISPR Therapeutics

Watchlist
52.330
+1.310+2.57%
Close  02/01 16:00 ET
52.250
-0.080-0.15%
Post Mkt Price 02/01 19:06 ET
High
53.040
Open
51.570
Turnover
55.52M
Low
50.340
Pre Close
51.020
Volume
1.08M
Market Cap
4.10B
P/E(TTM)
Loss
52wk High
86.950
Shares
78.29M
P/E(Static)
11.13
52wk Low
38.940
Float Cap
4.02B
Bid/Ask %
-33.33%
Historical High
220.200
Shs Float
76.87M
Volume Ratio
1.14
Historical Low
11.630
Dividend TTM
--
Div Yield TTM
--
P/B
2.10
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
1.40%
Amplitude
5.29%
Avg Price
51.598
Lot Size
1
Float Cap
4.02B
Bid/Ask %
-33.33%
Historical High
220.200
Shs Float
76.87M
Volume Ratio
1.14
Historical Low
11.630
Dividend TTM
--
P/B
2.10
Dividend LFY
--
Turnover Ratio
1.40%
Amplitude
5.29%
Avg Price
51.598
Lot Size
1
Price Forecast

News

Comment

Company Overview More
CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.
CEO: Dr. Samarth Kulkarni, PhD
Market: NASDAQ
Listing Date: 10/19/2016
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist